Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Bleeding and thrombosis in patients receiving chimeric antigen receptor T-cell therapy
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Authors
Chimeric antigen receptor (CAR) T-cell therapy has transformed the management of relapsed or refractory hematologic malignancies but is accompanied by immune-mediated toxicities that may disrupt hemostatic balance. In addition to cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and cytopenias, emerging data suggest an increased incidence of both thrombotic and bleeding complications following CAR T-cell infusion. We conducted a narrative review to evaluate the incidence, timing, risk factors, mechanisms, and management of CAR T-cell–associated coagulopathy, including 5 phase III randomized controlled trials and 11 observational studies published after 2020. Venous thromboembolism (VTE) was the most frequently reported thrombotic event, with rates ranging from 0.48–3.26% in trials and 2.1–10.8% in observational cohorts, typically occurring within the first 30–90 days post-infusion and often overlapping with CRS or ICANS. Arterial events were less common (<2%). Reported bleeding rates were low in trials (0–1.85%) but higher in observational studies (2.8–12.5%), frequently associated with thrombocytopenia, hypofibrinogenemia, and markers of endothelial activation. Anticoagulation for established VTE did not appear to confer excess major bleeding in limited series. Current evidence does not support routine thromboprophylaxis for all CAR T-cell recipients. Instead, thrombotic and hemorrhagic risks appear intertwined and temporally dynamic, driven by inflammation, endothelial injury, and cytopenias. Prospective studies incorporating standardized endpoint adjudication and risk stratification are needed to inform individualized prevention and management strategies.
Downloads
Download data is not yet available.
Citations
1. Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA 2024;332:1924. DOI: https://doi.org/10.1001/jama.2024.19462
2. Zhang X, Zhu L, Zhang H, et al. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol 2022;13:927153. DOI: https://doi.org/10.3389/fimmu.2022.927153
3. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388-98. DOI: https://doi.org/10.1158/2159-8290.CD-12-0548
4. Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol 2024;21:501–21. DOI: https://doi.org/10.1038/s41571-024-00903-0
5. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625–38. DOI: https://doi.org/10.1016/j.bbmt.2018.12.758
6. Peng X, Zhang X, Zhao M, et al. Coagulation abnormalities associated with CAR ‐T‐cell therapy in haematological malignancies: A review. Br J Haematol 2024;205:420–8. DOI: https://doi.org/10.1111/bjh.19583
7. Schorr C, Forindez J, Espinoza-Gutarra M, et al. Thrombotic events are unusual toxicities of chimeric antigen receptor T-cell therapies. Int J Mol Sci 2023;24:8349. DOI: https://doi.org/10.3390/ijms24098349
8. Bindal P, Patell R, Chiasakul T, et al. A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost 2024;22:2071–80. DOI: https://doi.org/10.1016/j.jtha.2024.03.021
9. Johnsrud A, Craig J, Baird JH, et al. Bleeding and thrombosis are associated with endothelial dysfunction in CAR-T cell therapy and are increased in patients experiencing neurologic toxicity. Blood 2020;136:32–3. DOI: https://doi.org/10.1182/blood-2020-142218
10. Johnsrud A, Craig J, Baird J, et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Adv 2021;5:4465–75. DOI: https://doi.org/10.1182/bloodadvances.2021004716
11. Hashmi H, Mirza AS, Darwin A, et al. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv 2020;4:4086–90. DOI: https://doi.org/10.1182/bloodadvances.2020002060
12. Wang X, Li C, Luo W, et al. IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy. Ann Hematol 2023;102:3575–85. DOI: https://doi.org/10.1007/s00277-023-05477-y
13. Goldman A, Maor E, Bomze D, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol 2021;78:1800–13. DOI: https://doi.org/10.1016/j.jacc.2021.08.044
14. Melody M, Gandhi S, Saunders H, et al. Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. Leuk Lymphoma 2022;63:1363–8. DOI: https://doi.org/10.1080/10428194.2022.2030475
15. Qi J, Lv X, Chen J, et al. TNF‐α increases the risk of bleeding in patients after CAR T‐cell therapy: A bleeding model based on a real‐world study of Chinese CAR T Working Party. Hematol Oncol 2022;40:64–72. DOI: https://doi.org/10.1002/hon.2931
16. Parks AL, Kambhampati S, Fakhri B, et al. Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma. Leuk Lymphoma 2021;62:1003–6. DOI: https://doi.org/10.1080/10428194.2020.1852474
17. Galli E, Sorà F, Hohaus S, et al. Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with ANTI‐CD19 CAR‐T cells. Br J Haematol 2023;201:86–94. DOI: https://doi.org/10.1111/bjh.18596
18. Ko A, Mutsaers P, Van Kleij L, et al. High risk of bleeding following CAR T-cell therapy: insights from the dutch “Follow that CAR!” registry. Blood 2025;146:315. DOI: https://doi.org/10.1182/blood-2025-315
19. Melo Garcia L, Wang TF, Kennah M, et al. Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience. Blood 2025;146:4496. DOI: https://doi.org/10.1182/blood-2025-4496
20. Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022;386:629–39. DOI: https://doi.org/10.1056/NEJMoa2116596
21. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386:640–54. DOI: https://doi.org/10.1056/NEJMoa2116133
22. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388:1002–14. DOI: https://doi.org/10.1056/NEJMoa2213614
23. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389:335–47. DOI: https://doi.org/10.1056/NEJMoa2303379
24. Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023;141:1675–84. DOI: https://doi.org/10.1182/blood.2022018730
25. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207–14. DOI: https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
26. Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010;8:2063–5. DOI: https://doi.org/10.1111/j.1538-7836.2010.03975.x
27. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:2119–26. DOI: https://doi.org/10.1111/jth.13140
28. Rejeski K, Sanz J, Fei T, et al. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood 2025;146:834–46. DOI: https://doi.org/10.1182/blood.2025028833
29. Luft T, Benner A, Jodele S, et al. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol 2017;4:e414–23. DOI: https://doi.org/10.1016/S2352-3026(17)30108-4
30. Demosthenous C, Evangelidis P, Gatsis A, et al. Endothelial injury following CAR-T cell immunotherapy for hematological malignancies. Cancers 2025;17:2876. DOI: https://doi.org/10.3390/cancers17172876
31. Calverley DC, Leader A, Cheong MA, et al. Inconsistent and inaccurate cancer clinical trial reporting of venous and arterial thrombotic events: an urgent call to action. J Clin Oncol 2025;43:2851–5. DOI: https://doi.org/10.1200/JCO-25-00489
32. Buechner J, Grupp SA, Hiramatsu H, et al. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv 2021;5:593–601. DOI: https://doi.org/10.1182/bloodadvances.2020002757
33. Belbachir S, Tudesq JJ, Lamure S, et al. Coagulopathy following chimeric antigen receptor T cell therapy in R/R adult B cell malignancies: a single center experience. Blood 2021;138:4839. DOI: https://doi.org/10.1182/blood-2021-152465
34. Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982;35:667–72. DOI: https://doi.org/10.1136/jcp.35.6.667
35. Besser MW, MacDonald SG. Acquired hypofibrinogenemia: current perspectives. J Blood Med 2016;7:217–25. DOI: https://doi.org/10.2147/JBM.S90693
36. Aurousseau MH, Levacher S, Bénéton C, et al. Transient dysfibrinogenemia and thrombocytopenia associated with recurrent acute pancreatitis in the course of isotretinoin therapy. [Article in French]. Rev Med Interne 1995;16:622–5. DOI: https://doi.org/10.1016/0248-8663(96)80763-6
37. Hauser E, Seidl R, Freilinger M, et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 1996;18:105–9. DOI: https://doi.org/10.1016/0387-7604(95)00139-5
38. Hines MR, Knight TE, McNerney KO, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther 2023;29:438.e1-e16.
39. Jiang H, Liu L, Guo T, et al. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol 2019;98:1721–32. DOI: https://doi.org/10.1007/s00277-019-03685-z
40. Perl M, Herfeld K, Harrer DC, et al. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies. Haematologica 2024;109:2969–77. DOI: https://doi.org/10.3324/haematol.2023.284564
Supporting Agencies
This study was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748How to Cite
1.
Lee D, Lage Bodour Danielian PL, Leader A. Bleeding and thrombosis in patients receiving chimeric antigen receptor T-cell therapy. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/461
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
